{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:47:35Z","timestamp":1761976055840,"version":"3.40.5"},"reference-count":12,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Dermatol"],"abstract":"<jats:p>The large cell transformation of mycosis fungoides (MF-LCT) is a phenomenon observed in the advanced stages of mycosis fungoides (MF), which is the most common primary cutaneous lymphoma. The diagnostic criteria of MF-LCT are a minimum of 25% of large cells or a formation of microscopic nodules of them in the histological examination of skin samples. The clinical outcomes for MF-LCT are poor, as less than 20% of patients survive 5 years after diagnosis, but the expression of the CD30 antigen is generally considered to be associated with a better prognosis. We present a case of a patient with the diagnosis of MF with LCT, with an ulcerated tumor lesion approximately 30 \u00d7 20 cm in size on the right lateral abdominal wall. Brentuximab vedotin (BV) treatment was started due to the presence of the CD30 antigen, with a quick and impressive regression of the cutaneous lesion and tumor mass and good treatment tolerance. After follow-up of 20 months, patient remains in complete remission. A schedule of treatment for MF-LCT is directed mainly by the clinical stage of the disease and the comorbidities; the more severe clinical course of the disease requires systemic treatment. If at least 5% of the cells found in the skin lesions biopsy sample express the CD30 antigen, a beneficial effect of BV treatment could be expected. It may seem that the use of BV is one of the optimal therapeutic options in patients with advanced MF-LCT showing expression of CD30. <\/jats:p>","DOI":"10.1159\/000529576","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T21:13:20Z","timestamp":1689887600000},"page":"110-116","source":"Crossref","is-referenced-by-count":2,"title":["Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT"],"prefix":"10.1159","volume":"15","author":[{"given":"Agnieszka","family":"Giza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karol","family":"Miklusiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Przemys\u0142aw","family":"Ha\u0142ubiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Jaworek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4117-3667","authenticated-orcid":false,"given":"Dagmara","family":"Zimowska-Cury\u0142o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Dyduch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Sacha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25577"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2850"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.11604\/pamj-cm.2020.2.104.21255"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000166"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376319"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.2016.0502"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18535"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.018"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.3787"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.054"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.11.013"}],"container-title":["Case Reports in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/cde\/article-pdf\/15\/1\/110\/4113458\/000529576.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/cde\/article-pdf\/15\/1\/110\/4113458\/000529576.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:14:50Z","timestamp":1745421290000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000529576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,21]]}},"URL":"https:\/\/doi.org\/10.1159\/000529576","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.23522862","asserted-by":"subject"}]},"ISSN":["1662-6567"],"issn-type":[{"type":"electronic","value":"1662-6567"}],"subject":[],"published":{"date-parts":[[2023,7,14]]}}}